Drug Profile
SN 2310
Alternative Names: SN 2310 Injectable Emulsion; SN2310; TOCOSOL CamptothecinLatest Information Update: 20 Apr 2012
Price :
$50
*
At a glance
- Originator Sonus Pharmaceuticals
- Developer OncoGenex Pharmaceuticals
- Class Antineoplastics; Camptothecins
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 30 Mar 2011 Discontinued - Phase-I for Solid tumours in USA (IV)
- 10 Nov 2008 OncoGenex Pharmaceuticals completes enrolment in its phase1 trial for solid tumours in USA
- 21 Aug 2008 OncoGenex Technologies has merged with Sonus Pharmaceuticals to form OncoGenex Pharmaceuticals